• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172622 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  " i9 N( u8 I# H
( J3 g* V# i! c6 c% r

) ~! B& T9 E$ q) H$ FSub-category:
4 E3 A0 b- b* M, I# J9 oMolecular Targets / H. n+ q2 p0 `: z) M

% A/ E4 [5 o! |4 c" I9 g* Y0 Q' k+ i
* t- B, ?6 ~- @8 ]' w1 c7 `6 ?Category:
! i1 f! B: ^1 `- S5 WTumor Biology
- z5 J8 e- v7 V& x2 C: J  K* t. R% {' `4 _* k6 B1 {# W/ b3 w, Q
" H! p; Y+ a% \+ u. e" w* O
Meeting:9 I( {, u5 r. h( F% s  e
2011 ASCO Annual Meeting
4 s6 N  s( O1 Q. F- w; a; ]
0 ?- ]' F7 K$ M* W: _
6 M/ Q& z: F( Y0 ~+ V! b) vSession Type and Session Title:/ t: \# @9 i) _' o, u
Poster Discussion Session, Tumor Biology : J5 x7 D" b  D- |0 I7 f% C1 l& [
& R* ?  @, j3 z  E) r$ Q; [

$ ]. ?. {5 o( P0 DAbstract No:* ]5 T9 c/ [6 H; H; `, i9 z
10517 2 e" B6 t/ N( k. u& u

/ }9 y% f: L) x+ e
7 Z& [3 u# ~( ]Citation:  W2 {; ?) C# Y5 m
J Clin Oncol 29: 2011 (suppl; abstr 10517)
; [2 q: h$ Z4 {. z& G! B
! V- t8 m; S; {6 b6 u# b8 ^) Z" u. h
Author(s):2 |( E, I+ c/ }$ E2 `
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China # `6 X* G: x0 z1 I1 \- \/ P

0 l/ ?# Y# T9 y+ ]" D
: k# O: k9 ^9 j0 I! |& L" s* y4 [( Q! r
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
" Z% [! J$ S1 v% I: h
, Y! _% J! _4 r' l' |1 LAbstract Disclosures
/ z1 G6 u, H/ {" }, t7 f$ f, H  H/ f# b  R: t7 x# Q/ v
Abstract:
( o8 n) c2 V0 X& B) e  a
3 S7 t8 B4 |  L9 _
6 Q8 K5 p, f5 s/ i' l0 |; qBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 V* Y1 y) ]" `) o% D- z3 K# c8 D6 ^! T/ a8 F: `9 W9 A

4 |2 i& r* C/ s9 w, T
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
1 b5 e( ~% K. U4 y没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
- x6 ^) @+ S" Y3 \6 |4 o* g' @
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 * e% ?% h7 m' ?) C
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
" a! X5 k( m* x- z* c0 G6 GALK一个指标医院要900多 ...
" \) P" Q, z! h; R- l
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
7 o7 @3 P- d+ J9 j# j5 _& h# b1 b; e$ l, g& U
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表